| 摘要 |
PROBLEM TO BE SOLVED: To obtain the subject agent extremely useful for preventing hypometropia or hypermetropia because of having the extension/contraction control action of ocular axial length, and besides, highly effective for producing an experimental animal model with perfect axial hypometropic or hypermetropic eyes containing no index hypometropia or hypermetropia. SOLUTION: This ocular axial length control agent contains a TGF-βregulator as active ingredient; specifically, an ocular axial length extension inhibitor contains a TGF-βactivator, esp. plasminogen activator as active ingredient, being a hypometropia preventive and therapeutic agent; and, an ocular axial length extender contains a TGF-βactivation inhibitor, esp. plasminogen activating factor inhibitor as active ingredient, being a hypermetropia preventive and therapeutic agent. The above agents are medicinal preparations for ocular use on a local basis.
|
